Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition

• US 20050148673A1
• Filed: 02/23/2003
• Published: 07/07/2005
• Est. Priority Date: 07/11/2002
• Status: Abandoned Application

• Current Assignee: Graeme E. Correll, John W. Olney, Ronald E. Harbut
• Original Assignee: Graeme E. Correll, John W. Olney, Ronald E. Harbut
• Inventors: Harbut, Ronald E., Correll, Graeme E., Olney, John W.
• Application Number:
  US10/373,433
• Publication Number:
  US 20050148673A1
• Time in Patent Office: Days
• US Class Current: 514/650
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 33/06 Aluminium, calcium or magnesium; Compounds thereof , e.g. clay
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A drug that inhibits NMDA receptors (such as ketamine, a surgical anesthetic) is continuously administered to patients suffering from neuropathic pain. Unless the NMDA antagonist drug has inherent safening activity, this treatment requires a “safener” drug to prevent the neurotoxic side effects of NMDA antagonists. One class of safener drugs that increase the efficacy of the treatment include alpha-2 adrenergic agonists, such as clonidine. The treatment lasts for several days and nights, continuously. A maximum tolerated dosage is titered for each patient, such as by observing slurring of speech, and the patient does not lose consciousness except during normal sleep. Magnesium and/or drugs that inhibit ketamine-degrading enzymes can also be used. Patients who suffered for years from chronic intractable pain emerged from this treatment with apparently permanent relief, or with lasting reductions in their levels of pain.

Claims

1. A method for treating chronic pain, comprising the steps of administering to a patient in need of such treatment:

a. at least one NMDA receptor antagonist drug, at a sustained dosage which is able to substantially reduce the patient'"'"'s chronic pain, and over a continuous period of time, wherein that dosage level over that period of time has been shown in previous human treatments to provide long-lasting relief from chronic pain even after administration of the NMDA receptor antagonist drug has been discontinued; and

,

b. at least one safener drug, at a concentration which has been shown, using in vivo animal tests, to reduce neurotoxic damage caused by potent NMDA receptor antagonist drugs in the absence of a safener drug.

2. The method of claim 1, wherein the NMDA receptor antagonist drug comprises ketamine, and wherein the ketamine is administered to the patient by intravenous infusion over a continuous period of at least 36 hours, at a dosage which is sufficient to establish and sustain a blood concentration of at least about 200 nanograms of ketamine per milliliter of blood plasma for a period of at least about 24 hours.

3. The method of claim 2, wherein the ketamine is administered to the patient at a dosage which is sufficient to establish and sustain a blood concentration of at least about 250 nanograms of ketamine per milliliter of blood plasma for a period of at least about 40 hours.

4. The method of claim 1, wherein the safener drug has also been shown in human treatments to potentiate the pain-relieving efficacy of the NMDA receptor antagonist drug.

5. The method of claim 4, wherein the safener drug comprises an alpha-2 adrenergic agonist drug.

6. The method of claim 5, wherein the alpha-2 adrenergic agonist drug is selected from the group consisting of clonidine, iodoclonidine, guanabenz, xylazine, medetomidine, tizanidine, rilmenidine, alpha-methyldopa, alpha-methylnoradrenaline, guanfacine, dexmedetomidine, azepexole, and lofexidine.

7. The method of claim 2, wherein the safener drug comprises an alpha-2 adrenergic agonist drug.

8. The method of claim 7, wherein the alpha-2 adrenergic agonist drug is selected from the group consisting of clonidine, iodoclonidine, guanabenz, xylazine, medetomidine, tizanidine, rilmenidine, alpha-methyldopa, alpha-methylnoradrenaline, guanfacine, dexmedetomidine, azepexole, and lofexidine.

9. The method of claim 1, wherein the safener drug acts as a direct agonist at GABA receptors even in the absence of naturally-occurring GABA.

10. The method of claim 9, wherein the direct GABA agonist is selected from the group consisting of propofol, pentobarbital, secobarbital, and thiamylal, and analogs and derivatives thereof which are active as direct GABA agonists.

11. The method of claim 1, wherein a water-soluble magnesium salt is also administered to the patient.

12. The method of claim 2, wherein a water-soluble magnesium salt is also administered to the patient.

13. A method for treating chronic pain, comprising the step of intravenously injecting into a patient in need of such treatment at least one NMDA receptor antagonist drug, at a sustained dosage over a period of time wherein that dosage over that period of time will provide lasting relief from chronic or neuropathic pain even after administration of the NMDA receptor antagonist drug has been discontinued.

14. The method of claim 13 wherein the NMDA receptor antagonist drug has an inherent safening activity due to activity at a second type of neuronal receptor.

15. The method of claim 14 wherein the NMDA receptor drug which has inherent safening activity is selected from the group consisting of ibogaine, ibogamine, eliprodil, ifenprodil, and analogs and derivatives thereof which are active as NMDA antagonists.

16. The method of claim 13 wherein the NMDA receptor antagonist drug comprises ketamine, and wherein the sustained dosage over a continuous period of time is able to establish ketamine levels in circulating blood plasma of at least about 200 nanograms of ketamine per milliliter of blood plasma, for at least 24 hours continuously.

17. The method of claim 13 wherein at least one safener drug which can reduce neurotoxic side effects of potent NMDA receptor antagonist drugs in animal tests is coadministered to the patient along with the NMDA receptor antagonist drug.

18. The method of claim 17, wherein the safener drug comprises an alpha-2 adrenergic agonist drug.

19. The method of claim 18, wherein the alpha-2 adrenergic agonist drug is selected from the group consisting of clonidine, iodoclonidine, guanabenz, xylazine, medetomidine, tizanidine, rilmenidine, alpha-methyldopa, alpha-methylnoradrenaline, guanfacine, dexmedetomidine, azepexole, and lofexidine.

20. The method of claim 13, wherein a water-soluble magnesium salt is also administered to the patient.

21. A composition of matter, comprising an injectable aqueous mixture of an NMDA receptor antagonist drug and an alpha-2 agonist drug, wherein each drug is present in the aqueous mixture at a concentration which is suited for intravenous infusion into a patient over a prolonged span of time in a dosage regimen capable of providing permanent relief from a neuropathic pain disorder.

22. The composition of matter of claim 21, wherein the NMDA receptor antagonist drug comprises ketamine, and wherein the injectable aqueous mixture also contains at least one safener drug that can reduce neurotoxic side effects of potent NMDA receptor antagonist drugs in animal tests.

23. The composition of matter of claim 22, wherein the safener drug comprises an alpha-2 adrenergic agonist drug.

24. The composition of matter of claim 21, wherein the injectable aqueous mixture also contains a magnesium salt.

25. An article of manufacture, comprising an injectable aqueous formulation containing at least one NMDA antagonist drug, enclosed within a package that maintains sterility of the aqueous formulation and that contains printed information stating that the NMDA antagonist drug is intended for sustained intravenous infusion for several days continuously, at a dosage which must be titrated individually for a specific patient who receives such treatment.

26. The article of manufacture of claim 25, wherein the aqueous formulation also contains at least one safener drug that can reduce neurotoxic side effects of potent NMDA receptor antagonist drugs in animal tests.

27. The article of manufacture of claim 25, wherein the aqueous formulation also contains a magnesium salt.